Boston Commerce Limited (BOSTONBIO) — shareholding pattern, promoter holding, financials and share price
About Boston Commerce Limited (BOSTONBIO)
Boston Commerce Limited operates in the Healthcare Service Provider industry, within the Healthcare sector. It trades on the NSE as BOSTONBIO and on the BSE under scrip code 531458. Its ISIN is INE109B01019.
Incorporated in 1995, Boston Bio Systems Ltd is in the business of trading in goods e.g. Medical equipment, testing kits, instruments etc. [1]
Boston Bio Systems Limited is primarily engaged in trading medical equipment, testing kits, and instruments.
Originally founded in 1995, the company started with share broking and trading in shares and derivatives.
Listed peers in Healthcare Service Provider: Dhanvantri Jeevan Rekha Ltd, Clinitech Laboratory Ltd, Looks Health Services Ltd, Dr Lalchandani Labs Ltd, Ashram Online.com Ltd, Gian Lifecare Ltd.
Valuation & Returns
10 Jul 2026At ₹5.33 a share on 10 Jul 2026, Boston Commerce Limited (BOSTONBIO) was valued at a price-to-book of 0.63x on a book value of ₹8.43 per share as of Mar 2025. Solomo computes return on equity of -9.82% and return on capital employed of 0.16% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- Industry P/E
- 61.73x
- P/B
- 0.63x
- EPS (TTM)
- ₹-0.83
- Book value / share
- ₹8.43
- ROE
- -9.82%
- ROCE
- 0.16%
- ROA
- -3.89%
- Debt / equity
- 0.92x
- Dividend yield
- 0%
- EBITDA margin
- 27.08%
- 52-week range
- ₹5.13 – ₹10.95
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Boston Commerce Limited (BOSTONBIO) reported revenue of ₹0.48 crore, net profit of ₹-0.58 crore and earnings per share of ₹-0.83. That compares with revenue of ₹0.19 crore and net profit of ₹-0.55 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, net profit ₹-0.65 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 0 | 0 | 0 | 0.19 | 0.48 |
| Net profit (₹ cr) | 0 | 0 | -0.14 | -0.55 | -0.58 |
| EPS (₹) | 0 | 0 | -0.2 | -0.79 | -0.83 |
| Measure | 10Y | 1Y |
|---|---|---|
| Sales growth | -20.38% | - |
| Profit growth | - | -292.86% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 2.14% of Boston Commerce Limited (BOSTONBIO) (unchanged from the previous quarter) and domestic institutional investors (DII) hold 1.7%. Market capitalisation was ₹4 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: MAYANK DOSHI 2.6%, MANISHA H DABHI 2.18%, SANGITA PRADYUMAN SHAH 2.14%, UNICORN FUND 1.7%, AMARISH JAGMOHAN SHAH 1.69%, SURYANSH STOCK & SHARES PVT LTD 1.39%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 2.14% | - | - | 1.7% | 97.86% |
| Mar 2026 | 2.14% | - | - | 1.7% | 97.86% |
| Dec 2025 | 2.14% | - | - | 0% | 97.86% |
| Sep 2025 | 2.14% | - | - | - | 97.86% |
| Jun 2025 | 2.14% | - | - | - | 97.86% |
| Mar 2025 | 2.14% | - | - | - | 97.86% |
| Dec 2024 | 2.14% | - | - | - | 97.86% |
| Sep 2024 | 2.14% | - | - | - | 97.86% |